Phosphonoformic acid reduces hyperphosphatemia-induced vascular calcification via Pit-1

Area of Science:

• Cardiovascular Biology
• Renal Physiology
• Vascular Biology

Background:

• Hyperphosphatemia is a common complication in chronic kidney disease.
• Vascular calcification is associated with increased cardiovascular morbidity and mortality.
• The precise mechanisms linking hyperphosphatemia to vascular calcification require further elucidation.

Purpose of the Study:

• To investigate the role of phosphate cotransporter-1 (Pit-1) in hyperphosphatemia-induced vascular calcification (HPVC).
• To explore the potential of Pit-1 inhibition as a therapeutic strategy for HPVC.

Main Methods:

• Primary human aortic smooth muscle cells and rat aortic rings were cultured under varying phosphorus concentrations.
• The effects of Pit-1 inhibition using small interfering RNA and phosphonoformic acid (PFA) were assessed.
• Alizarin red staining, Pit-1 expression, and smooth muscle cell phenotypic markers were analyzed.

Main Results:

• Hyperphosphatemia upregulated Pit-1 expression and induced vascular smooth muscle cell phenotypic transition, leading to HPVC.
• Pit-1 inhibition via siRNA or PFA significantly reduced Pit-1 expression and attenuated HPVC.
• These findings were consistent in both cellular and organ models.

Conclusions:

• Pit-1 is a key mediator in the pathogenesis of HPVC.
• Phosphonoformic acid (PFA) shows therapeutic potential for HPVC by inhibiting Pit-1.
• Further clinical studies are necessary to validate PFA's safety and efficacy in patients.